Investigational drug · Phase 2
CD19
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for B-ALL.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 25, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1,294
Any phase or sponsor naming "CD19"
First trial start
2021
Mar 7, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CD19", any sponsor or status.
Conditions studied
As listed on its trial records.
- B-ALL
Largest trials
Live from ClinicalTrials.gov: studies naming "CD19" as an intervention, largest first.
- Harvesting Cells for Experimental Cancer TreatmentsEnrolling by invitation
National Cancer Institute (NCI)NIH
NCT00068003 · 7,000 participants (planned) · Start Sep 8, 2003
Drug: Anti-CD19 CAR PBL · For: Melanoma; Gastrointestinal Cancer; Metastatic Cancer and 2 more
Sites: Bethesda, Maryland
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic LeukemiaPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT03914625 · 6,720 participants (planned) · Start Jul 3, 2019 · Primary completion Sep 30, 2027
Drug: Asparaginase Erwinia chrysanthemi; Blinatumomab and 13 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Down Syndrome
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 228 sites in all
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyPivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT03959085 · 5,951 participants (planned) · Start Oct 31, 2019 · Primary completion Mar 31, 2032
Drug: Blinatumomab; Calaspargase Pegol and 14 more · For: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Central Nervous System Leukemia and 2 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 231 sites in all
- Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALLPivotal-lookingRecruiting
Bambino Gesù Hospital and Research InstituteAcademic, hospital or other
NCT07297914 · 1,000 participants (planned) · Start Jan 7, 2026 · Primary completion Nov 30, 2032
Drug: Blinatumomab; Cyclophosphamide and 1 more · For: Acute Lymphoblastic Leukemia (ALL); Stem Cell Transplant; Graft -Versus-host-disease
Sites: Vienna, Austria; Prague, Czechia; Copenhagen, Denmark · 9 sites in all
- Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL PatientsPivotal-lookingActive, not recruiting
Incyte CorporationIncyte (INCY)
NCT04824092 · 899 participants · Start May 11, 2021 · Primary completion Sep 1, 2026
Drug: Tafasitamab; Lenalidomide and 7 more · For: Diffuse Large B-cell Lymphoma
Sites: Daphne, Alabama; Anaheim, California; Clovis, California · 307 sites in all
- A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07735637 · 750 participants (planned) · Start Sep 24, 2026 · Primary completion Nov 2, 2028
Drug: AZD0120; Cyclophosphamide and 3 more · For: Newly Diagnosed Multiple Myeloma (NDMM)
Sites: Gilbert, Arizona; Goodyear, Arizona; Phoenix, Arizona · 114 sites in all
- Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCTPivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT07764978 · 750 participants (planned) · Start Jun 26, 2026 · Primary completion Jan 11, 2029
Drug: AZD0120; Daratumumab and 6 more · For: Newly Diagnosed Multiple Myeloma
Sites: Gilbert, Arizona; Phoenix, Arizona; Tucson, Arizona · 124 sites in all
Azienda USL Reggio Emilia - IRCCSGovernment (non-federal)
NCT04848493 · 747 participants · Start Apr 19, 2021 · Primary completion May 16, 2022
Drug: COVID-19 vaccines · For: COVID-19; Solid Tumor; Hematologic Diseases and 2 more
Sites: Bari, Italy; Bologna, Italy; Genova, Italy · 12 sites in all
- Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic LeukemiaPivotal-lookingActive, not recruiting
National Cancer Institute (NCI)NIH
NCT02101853 · 669 participants · Start Dec 17, 2014 · Primary completion Jun 30, 2021
Drug: Asparaginase; Blinatumomab and 14 more · For: Recurrent B Acute Lymphoblastic Leukemia
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 186 sites in all
- Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line TherapyPivotal-lookingActive, not recruiting
Kite, A Gilead CompanyGilead Sciences (GILD)
NCT07479797 · 550 participants (planned) · Start May 22, 2026 · Primary completion May 2031
Drug: KITE-753; Axicabtagene Ciloleucel and 2 more · For: Relapsed or Refractory Large B-cell Lymphoma
Sites: Goodyear, Arizona; Duarte, California; Stanford, California · 42 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Measurable Residual Disease.
Tembhare PR, Deshpande N, Ghogale S · Methods Mol Biol 2027
- Flow Cytometric Immunophenotyping of Acute Lymphoblastic Leukemia.
Delgado D, Cardinali JL, DiGiuseppe JA · Methods Mol Biol 2027
- Immunophenotyping of Human B Lymphocytes from Peripheral Blood Mononuclear Cells.
Lopez-Ocasio M, Lin WC, Hockman SC, et al. · Methods Mol Biol 2027
- Multiparametric Flow Cytometry Analysis of Naïve, Memory, and Effector T-Cells.
Chen CH, Dagur PK, Saxena A · Methods Mol Biol 2027
- Surface glycosylation of resveratrol-loaded PLGA nanoparticles modulates interfacial interactions with B lymphocytes.
Osorio-Muñoz E, Ruiz E, Orozco VH, et al. · Colloids Surf B Biointerfaces 2027
- Targeting CARM1 impairs DNA damage repair and attenuates B-cell acute lymphoblastic leukemia progression.
Liao P, Qiu Y, Li M, et al. · Biochim Biophys Acta Mol Basis Dis 2027
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.